EUVIMEDEUVIMED entdecken
Crossref

Gemcitabine Plus Oxaliplatin (GemOx) as Salvage Chemotherapy in Heavily Pre-treated Metastatic Castration-Resistant Prostate Cancer: A Single-Institution Retrospective Series

Chiara Ogliosi, Chiara Abeni, Angelo Peroni, Alberto Zaniboni

Journal of Cancer Science and Clinical Therapeutics · 2026 · 10 (03)

DOI: 10.26502/jcsct.5079287 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cancer Science and Clinical Therapeutics, 2026. Verfasst von Chiara Ogliosi und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Ogliosi, C., Abeni, C., Peroni, A., & Zaniboni, A. (2026). Gemcitabine Plus Oxaliplatin (GemOx) as Salvage Chemotherapy in Heavily Pre-treated Metastatic Castration-Resistant Prostate Cancer: A Single-Institution Retrospective Series. Journal of Cancer Science and Clinical Therapeutics, 10(03). https://doi.org/10.26502/jcsct.5079287

Vancouver

Ogliosi C, Abeni C, Peroni A, Zaniboni A. Gemcitabine Plus Oxaliplatin (GemOx) as Salvage Chemotherapy in Heavily Pre-treated Metastatic Castration-Resistant Prostate Cancer: A Single-Institution Retrospective Series. Journal of Cancer Science and Clinical Therapeutics. 2026;10(03). doi:10.26502/jcsct.5079287

BibTeX
@article{Ogliosi2026,
  author = {Ogliosi, Chiara and Abeni, Chiara and Peroni, Angelo and Zaniboni, Alberto},
  title = {Gemcitabine Plus Oxaliplatin (GemOx) as Salvage Chemotherapy in Heavily Pre-treated Metastatic Castration-Resistant Prostate Cancer: A Single-Institution Retrospective Series},
  journal = {Journal of Cancer Science and Clinical Therapeutics},
  year = {2026},
  volume = {10},
  number = {03},
  doi = {10.26502/jcsct.5079287}
}
Kostenlos starten →